EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ANI Pharmaceuticals's Enterprise Value is $2,243.6 Mil.
ANI Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $182.8 Mil. Therefore, ANI Pharmaceuticals's EV-to-FCF for today is 12.27.
The historical rank and industry rank for ANI Pharmaceuticals's EV-to-FCF or its related term are showing as below:
ANIP'
s EV-to-FCF Range Over the Past 10 Years
Min: -698.23 Med: -5.77 Max: 300.44
Current: 12.27
During the past 13 years, the highest EV-to-FCF of ANI Pharmaceuticals was 300.44. The lowest was -698.23. And the median was -5.77.
ANIP's EV-to-FCF is ranked better than 70.94% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs ANIP: 12.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ANI Pharmaceuticals (NAS:ANIP) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ANI Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
ANI Pharmaceuticals's share price for today is $86.03.
ANI Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ANI Pharmaceuticals EV-to-FCF Related Terms
ANI Pharmaceuticals EV-to-FCF Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's EV-to-FCF falls into.
ANI Pharmaceuticals's current Enterprise Value is $2,243.6 Mil.
ANI Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $182.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (ANIP) has a EV-to-FCF of 12.27 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ANI Pharmaceuticals and its competitors. According to the industry distribution chart, ANI Pharmaceuticals ranks #163 out of 561 companies in the Drug Manufacturers industry, placing it in the top 29.1%.
Is ANI Pharmaceuticals' EV-to-FCF too high?
ANI Pharmaceuticals' current EV-to-FCF is 12.27. The Drug Manufacturers industry median EV-to-FCF is 20.85. ANI Pharmaceuticals' value of 12.27 is 41.2% below this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #163 out of 561 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, ANI Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' EV-to-FCF compare to AMLX and TRLV?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #163 out of 561 companies for EV-to-FCF. This puts ANI Pharmaceuticals in the upper half of its industry. The industry median EV-to-FCF is 20.85. ANI Pharmaceuticals' value of 12.27 is 41.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current EV-to-FCF of 12.27 is 41.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current EV-to-FCF is 12.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (ANIP) is currently considered Modestly Undervalued. The stock's GF Value™ is $99.14, compared to a current price of $86.03 — trading 13.2% below its estimated fair value. The current EV-to-FCF is 12.27 and 41.2% below the Drug Manufacturers industry median of 20.85. ANI Pharmaceuticals' overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ANI Pharmaceuticals (ANIP), the current EV-to-FCF is 12.27 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (ANIP) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of $86.03 is trading 13.2% below its estimated GF Value™ of $99.14.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for ANIP:
EV-to-FCF: 12.27
GF Value™: $99.14 vs. price of $86.03 (13.2% below fair value)
Industry Position: 41.2% below the Drug Manufacturers median (#163 of 561)
No single metric tells the full story. See the ANIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
88GF Score
Get the complete analysis for ANIP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIP has been successfully added to your 
